Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Monte Rosa Therapeutics, Inc. - Common Stock
(NQ:
GLUE
)
20.17
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Monte Rosa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
November 13, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 07, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
↗
October 28, 2024
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 28, 2024
Via
Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
↗
October 28, 2024
Via
Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
October 28, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Why Is Monte Rosa Therapeutics Stock Surging On Monday?
↗
October 28, 2024
Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 28, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
October 28, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
October 23, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 19, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
July 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
May 21, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 16, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
May 16, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 15, 2024
Via
Benzinga
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 15, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
May 02, 2024
Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
March 26, 2024
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
March 26, 2024
Via
Benzinga
GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023
↗
March 14, 2024
GLUE stock results show that Monte Rosa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
